Kenvue & Robert F. Kennedy Jr.

Kenvue: Kenvue, the maker of Tylenol, disputed any link between the drug and autism. Its shares fell 7.5% in trading, reducing its market value by about $2.6 billion due to Donald Trump's statements.

Robert F. Kennedy Jr.: Robert F. Kennedy Jr., as Health Secretary, is launching an 'all-agency' effort to identify causes of autism at Donald Trump's urging and has influenced vaccine policies, promoting debunked theories.

Kenvue: Kenvue, the manufacturer of Tylenol, refuted the claims made by Robert F. Kennedy Jr. and Donald Trump, stating that studies have found no causal link between acetaminophen use during pregnancy and fetal developmental issues.

Robert F. Kennedy Jr.: As the Health Secretary, Robert F. Kennedy Jr. made controversial and unproven claims linking Tylenol and circumcision to autism, drawing criticism from medical experts and potentially undermining public health policy.

Kenvue: Kenvue, the manufacturer of Tylenol, strongly disagreed with the suggestion that acetaminophen causes autism, defending the drug's safety and warning of risks from untreated fever or pain.

Robert F. Kennedy Jr.: Robert F. Kennedy Jr., as Health and Human Services Secretary, led the administration's autism initiative and promoted discredited theories linking vaccines to autism.

Kenvue: Kenvue, a spin-off of Johnson & Johnson, is a primary defendant in the United States — Texas lawsuit, accused of deceptively marketing Tylenol and facing claims of liability transfer from Johnson & Johnson. Kenvue's shares fell following the news.

Kenvue: Kenvue is being acquired by Kimberly-Clark for $48.7 billion, providing a significant premium to its shareholders. Kenvue's stock surged after the announcement, despite facing scrutiny over Tylenol and activist investor pressure.

Kenvue: Kenvue, the manufacturer of Tylenol (paracetamol), faced a lawsuit regarding alleged links between its product and autism, which was dismissed. The new study supports the safety of its product.